Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.